Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3.
de la Fouchardière C, Gamradt P, Chabaud S, Raddaz M, Blanc E, Msika O, Treilleux I, Bachy S, Cattey-Javouhey A, Guibert P, Sarabi M, Rochefort P, Funk-Debleds P, Coutzac C, Ray-Coquard I, Peyrat P, Meeus P, Rivoire M, Dupré A, Hennino A. de la Fouchardière C, et al. Among authors: coutzac c. J Pers Med. 2022 Apr 12;12(4):623. doi: 10.3390/jpm12040623. J Pers Med. 2022. PMID: 35455739 Free PMC article.
Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report.
Varnier R, Garrivier T, Hafliger E, Favre A, Coutzac C, Spire C, Rochefort P, Sarabi M, Desseigne F, Guibert P, Cattey-Javouhey A, Funk-Debleds P, Mastier C, Buisson A, Pérol D, Trédan O, Blay JY, Phelip JM, de la Fouchardiere C. Varnier R, et al. Among authors: coutzac c. Front Oncol. 2021 Sep 24;11:756365. doi: 10.3389/fonc.2021.756365. eCollection 2021. Front Oncol. 2021. PMID: 34631593 Free PMC article.
Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program.
Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C. Cassier PA, et al. Among authors: coutzac c. Transl Oncol. 2022 Jan;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15. Transl Oncol. 2022. PMID: 34794033 Free PMC article.
Immune checkpoint inhibitor sensitivity of DNA repair deficient tumors.
Rochefort P, Desseigne F, Bonadona V, Dussart S, Coutzac C, Sarabi M, la Fouchardiere C. Rochefort P, et al. Among authors: coutzac c. Immunotherapy. 2021 Oct;13(14):1205-1213. doi: 10.2217/imt-2021-0024. Epub 2021 Sep 8. Immunotherapy. 2021. PMID: 34494466 Review.
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer.
Heudel P, Chabaud S, Perol D, Flechon A, Fayette J, Combemale P, Tredan O, Desseigne F, de la Fouchardiere C, Boyle H, Perol M, Bachelot T, Cassier P, Avrillon V, Terret C, Michallet AS, Neidhardt-Berard EM, Nicolas-Virelizier E, Dufresne A, Belhabri A, Brahmi M, Lebras L, Nicolini F, Sarabi M, Rey P, Bonneville-Levard A, Rochefort P, Provensal AM, Eberst L, Assaad S, Swalduz A, Saintigny P, Toussaint P, Guillermin Y, Castets M, Coutzac C, Meeus P, Dupré A, Durand T, Crochet H, Fervers B, Gomez F, Rivoire M, Gregoire V, Claude L, Chassagne-Clement C, Pilleul F, Mognetti T, Russias B, Soubirou JL, Lasset C, Chvetzoff G, Mehlen P, Beaupère S, Zrounba P, Ray-Coquard I, Blay JY. Heudel P, et al. Among authors: coutzac c. ESMO Open. 2021 Feb;6(1):100044. doi: 10.1016/j.esmoop.2020.100044. Epub 2021 Jan 27. ESMO Open. 2021. PMID: 33516148 Free PMC article.
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer.
Coutzac C, Jouniaux JM, Paci A, Schmidt J, Mallardo D, Seck A, Asvatourian V, Cassard L, Saulnier P, Lacroix L, Woerther PL, Vozy A, Naigeon M, Nebot-Bral L, Desbois M, Simeone E, Mateus C, Boselli L, Grivel J, Soularue E, Lepage P, Carbonnel F, Ascierto PA, Robert C, Chaput N. Coutzac C, et al. Nat Commun. 2020 May 1;11(1):2168. doi: 10.1038/s41467-020-16079-x. Nat Commun. 2020. PMID: 32358520 Free PMC article.
Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study.
Varnier R, Toullec C, Philonenko S, Dupré A, Artru P, Hafliger E, Drouillard A, Torregrosa C, Pernot S, McLellan P, Lecomte T, Moulin V, Lécaille C, Touchefeu Y, Locher C, Taieb J, Coutzac C. Varnier R, et al. Among authors: coutzac c. Dig Liver Dis. 2024 Feb 24:S1590-8658(24)00270-6. doi: 10.1016/j.dld.2024.02.009. Online ahead of print. Dig Liver Dis. 2024. PMID: 38403514
Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.
De La Fouchardière C, Malka D, Cropet C, Chabaud S, Raimbourg J, Botsen D, Launay S, Evesque L, Vienot A, Perrier H, Jary M, Rinaldi Y, Coutzac C, Bachet JB, Neuzillet C, Williet N, Desgrippes R, Grainville T, Aparicio T, Peytier A, Lecomte T, Roth GS, Thirot-Bidault A, Lachaux N, Bouché O, Ghiringhelli F. De La Fouchardière C, et al. Among authors: coutzac c. J Clin Oncol. 2024 Mar 20;42(9):1055-1066. doi: 10.1200/JCO.23.00795. Epub 2024 Jan 17. J Clin Oncol. 2024. PMID: 38232341 Clinical Trial.
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort.
Taïeb J, Sayah L, Heinrich K, Kunzmann V, Boileve A, Cirkel G, Lonardi S, Chibaudel B, Turpin A, Beller T, Hautefeuille V, Vivaldi C, Mazard T, Bauguion L, Niger M, Prager GW, Coutzac C, Benedikt Westphalen C, Auclin E, Pilla L. Taïeb J, et al. Among authors: coutzac c. Eur J Cancer. 2023 Jul;188:90-97. doi: 10.1016/j.ejca.2023.04.012. Epub 2023 Apr 23. Eur J Cancer. 2023. PMID: 37229836
33 results